微信扫一扫
实时资讯全掌握
|
A private pharmaceutical firm is under consideration for acquisition where the financial buyer will pay with equity. Part of the payment to the sellers is based on FDA approval of the firm’s drug. If the analyst uses a market approach and comparable data from public firms, which of the following would most likely result in a price-multiple that is too high? The comparable data is: A. from transactions where the buyer used cash. B. for transactions where the consideration was non-contingent. C. for strategic buyers. |